Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
Kuo
Phillip H
PH
Kanal
Emanuel
E
Abu-Alfa
Ali K
AK
Cowper
Shawn E
SE
D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D005355:Fibrosis; D005682:Gadolinium / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000453:epidemiology; D008279:Magnetic Resonance Imaging / Q000009:adverse effects* / Q000706:statistics & numerical data; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012867:Skin / Q000473:pathology*; D012871:Skin Diseases / Q000139:chemically induced* / Q000453:epidemiology
D003287:Contrast Media; D005682:Gadolinium